Clinical Trial Update: Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating whether trimetazidine can prevent acute myocardial injury in patients hospitalized with COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Injury
• Respiratory Distress Syndrome

Drugs mentioned

• Trimetazidine (trimetazidine)

Snippet

Sponsor: Ministry of Health, Brazil | Conditions: Acute Respiratory Distress Syndrome, Covid19 | Phase 2 | Status: UNKNOWN